Variable | Overall survival | ||
---|---|---|---|
HR | 95% CI | p | |
Model A | |||
 Age less (61 or greater vs than 61) | 1.429 | 1.051–1.944 | 0.023 |
 Primary tumor (T) (III/IV vs I/II) | 2.370 | 1.517–3.702 | < 0.001 |
 Lymph nodes metastasis (N) (Yes Vs No) | 1.753 | 1.129–2.723 | 0.012 |
 TNM stage (III/IV vs I/II) | 1.013 | 0.576–1.782 | 0.964 |
 CD44 (high vs low) | 1.701 | 1.221–2.371 | 0.002 |
Model B | |||
 Age less (61 or greater vs than 61) | 1.510 | 1.113–2.050 | 0.008 |
 Primary tumor (T) (III/IV vs I/II) | 2.321 | 1.474–3.654 | < 0.001 |
 Lymph nodes metastasis (N) (Yes vs No) | 1.706 | 1.086–2.682 | 0.021 |
 TNM stage (III/IV vs I/II) | 0.987 | 0.554–1.759 | 0.964 |
 CD44v6 (Pos. vs Neg.) | 1.168 | 0.848–1.609 | 0.340 |
Model C | |||
 Age less (61 or greater vs than 61) | 1.493 | 1.100–2.027 | 0.010 |
 Primary tumor (T) (III/IV vs I/II) | 2.765 | 1.739–4.395 | < 0.001 |
 Lymph nodes metastasis (N) (yes vs no) | 1.818 | 1.167–2.833 | 0.008 |
 TNM Stage (III/IV vs I/II) | 0.827 | 0.461–1.485 | 0.525 |
 CD44v8-10 (Pos. vs Neg.) | 1.694 | 1.234–2.326 | 0.001 |
Model E | |||
 Age less (61 or greater vs than 61) | 1.509 | 1.112–2.047 | 0.008 |
 Primary tumor (T) (III/IV vs I/II) | 2.411 | 1.545–3.764 | < 0.001 |
 Lymph nodes metastasis (N) (yes vs no) | 1.724 | 1.104–2.691 | 0.017 |
 TNM stage (III/IV vs I/II) | 0.955 | 0.539–1.693 | 0.875 |
 ALDH1A1 (high vs low) | 0.867 | 0.636–1.182 | 0.366 |